Success Metrics

Clinical Success Rate
81.0%

Based on 17 completed trials

Completion Rate
81%(17/21)
Active Trials
1(4%)
Results Posted
65%(11 trials)
Terminated
4(17%)

Phase Distribution

Ph phase_1
7
30%
Ph phase_4
5
22%
Ph phase_3
4
17%
Ph phase_2
5
22%
Ph not_applicable
1
4%

Phase Distribution

7

Early Stage

5

Mid Stage

9

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
7(31.8%)
Phase 2Efficacy & side effects
5(22.7%)
Phase 3Large-scale testing
4(18.2%)
Phase 4Post-market surveillance
5(22.7%)
N/ANon-phased studies
1(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.3%

17 of 22 finished

Non-Completion Rate

22.7%

5 ended early

Currently Active

1

trials recruiting

Total Trials

23

all time

Status Distribution
Active(1)
Completed(17)
Terminated(5)

Detailed Status

Completed17
Terminated4
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
1
Success Rate
81.0%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (31.8%)
Phase 25 (22.7%)
Phase 34 (18.2%)
Phase 45 (22.7%)
N/A1 (4.5%)

Trials by Status

withdrawn14%
terminated417%
active_not_recruiting14%
completed1774%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT00980538Phase 3

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

Active Not Recruiting
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT04208373Phase 1

A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants

Completed
NCT00537394Phase 3

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

Completed
NCT01641367Phase 4

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Completed
NCT00823979Phase 2

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Terminated
NCT00855335Phase 3

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Completed
NCT02818348Phase 1

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

Completed
NCT01199731Phase 2

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

Terminated
NCT00855413Phase 4

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

Terminated
NCT01422330Phase 4

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Completed
NCT01254656Phase 2

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Terminated
NCT01199939Phase 2

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

Completed
NCT01876966Phase 1

Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine

Completed
NCT01090648Phase 1

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

Completed
NCT00867152Phase 1

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Completed
NCT00782301Phase 4

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Withdrawn
NCT00792584Not Applicable

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz

Completed
NCT00855088Phase 1

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

Completed
NCT01121809Phase 4

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23